Sermorelin Standard Titration Schedule

What Is the Standard Sermorelin Titration Schedule?

The standard adult titration begins at 100 to 200 mcg subcutaneously once nightly and steps up by 100 mcg every two to four weeks until IGF-1 lands in the age-adjusted reference range or side effects appear. Because sermorelin is a growth hormone-releasing hormone (GHRH) analogue, its effects accumulate over weeks rather than days. Jumping the dose too fast produces flushing, headache, and fluid retention without proportional IGF-1 gain.

Most adults stabilize between 200 and 500 mcg per night. A minority of patients with significant somatotroph reserve may respond adequately at 100 mcg; others with blunted pituitary response may require 600 mcg, though evidence above 500 mcg in healthy adults is limited to case series rather than randomized controlled trials.

Why Nightly Dosing Matters

Growth hormone secretion is highest during the first slow-wave sleep cycle, roughly 60 to 90 minutes after sleep onset. Injecting sermorelin 30 to 60 minutes before bed amplifies this natural pulse rather than creating an out-of-phase spike. A 1990 randomized trial by Walker et al. (N=53 children with GH deficiency) demonstrated that once-nightly subcutaneous administration of 30 mcg/kg produced statistically significant increases in mean height velocity compared with placebo over 6 months (P<0.005) [1]. Timing alignment with endogenous pulsatility is built into every reputable titration protocol.

Rotation of Injection Sites

Injecting the same site nightly causes lipohypertrophy. Rotate among the abdomen (at least 2 inches from the navel), anterior thigh, and the lateral deltoid region on a weekly schedule. Document injection sites in a logbook or phone note to avoid unintentional clustering.

How to Start Sermorelin: Week-by-Week Dose Escalation

The table below reflects the protocol used at HealthRX and is consistent with compounding pharmacy labeling and published titration arms.

| Week | Dose | Action | |------|------|--------| | 1 to 2 | 100 mcg nightly | Baseline IGF-1 drawn before first dose | | 3 to 4 | 200 mcg nightly | Escalate if no limiting side effects | | 5 to 8 | 300 mcg nightly | Check IGF-1 at week 6 | | 9 to 12 | 400 mcg nightly (if IGF-1 below mid-range) | Continue only if IGF-1 not yet at target | | 13+ | 500 mcg nightly (maximum for most protocols) | Recheck IGF-1 at week 14; hold dose |

Patients whose IGF-1 reaches the age-adjusted mid-range (typically 150 to 300 ng/mL for adults aged 30 to 59) at any step should hold the dose at that level and recheck labs in 6 to 8 weeks before any further change [2].

When to Slow the Escalation

Move from a two-week to a four-week interval when any of the following appear:

• Persistent morning edema in the hands or feet
• Carpal tunnel symptoms (numbness, tingling in the first three fingers)
• Arthralgia in the wrists or knees
• Fasting glucose rise above 100 mg/dL on repeat measurement

These are dose-related effects of elevated IGF-1 activity, not idiosyncratic drug reactions. Slowing the escalation almost always resolves them without stopping therapy entirely [3].

When to Drop Back One Step

A dose reduction of 100 mcg is appropriate if IGF-1 exceeds the upper limit of the age-adjusted reference range on two consecutive lab draws, if carpal tunnel symptoms persist after a four-week pause in escalation, or if a patient reports disrupted sleep quality that cannot be attributed to another cause. Drop back, recheck IGF-1 in four weeks, and document the change in the medical record.

IGF-1 Monitoring During Titration

Insulin-like growth factor 1 (IGF-1) is the primary biomarker for tracking sermorelin response. It is produced primarily in the liver in response to GH stimulation and has a half-life of 12 to 15 hours, making it far more stable than GH itself, which fluctuates minute to minute.

Target Ranges by Age

The Endocrine Society clinical practice guideline on adult GH deficiency (2011, updated 2019) states that IGF-1 should be maintained "within the age- and sex-normalized reference range, ideally in the mid-normal range, to avoid the adverse effects associated with excess GH action" [4]. Reference ranges vary by assay; always compare to the lab's own age-stratified normal intervals.

General targets used at HealthRX:

| Age Range | IGF-1 Target (ng/mL) | |-----------|----------------------| | 25 to 34 | 175 to 325 | | 35 to 44 | 150 to 290 | | 45 to 54 | 130 to 265 | | 55 to 65 | 110 to 230 |

These are approximate. Lab-specific reference intervals take precedence.

Monitoring Schedule

• Baseline: Draw IGF-1 before the first injection.
• Week 6: First on-therapy draw, typically after reaching 300 mcg.
• Every 4 to 6 weeks during active escalation.
• Every 3 months once on stable maintenance dose.
• Annually once two consecutive in-range results are confirmed.

A morning fasting blood draw is preferred. IGF-1 does not require special timing relative to the injection because its half-life smooths out pulsatile GH release [5].

Pediatric Dosing: What the Original Trials Show

Sermorelin acetate received FDA approval (brand name Geref, Serono) for treating idiopathic GH deficiency in prepubertal children. The Walker et al. 1990 trial (N=53) used 30 mcg/kg/day as a fixed dose given subcutaneously once nightly [1]. Over 6 months, treated children gained a mean height velocity of 8.1 cm/year versus 3.6 cm/year in the placebo group. IGF-1 and IGF-binding protein 3 (IGFBP-3) both rose significantly, confirming pituitary GH axis stimulation rather than exogenous GH replacement.

Pediatric dosing is weight-based and is not directly extrapolated to adults. Adult off-label use relies on fixed-dose titration because adults' somatotroph reserve is assessed by IGF-1 response rather than growth velocity. Any pediatric use must be managed by a pediatric endocrinologist, not a telehealth platform.

How Quickly Can You Increase Sermorelin?

The minimum safe escalation interval is two weeks for most patients. Moving faster does not accelerate IGF-1 normalization because the pituitary requires several weeks to upregulate somatotroph sensitivity. A 2003 pharmacokinetic review of GHRH analogues noted that steady-state IGF-1 response to a new dose level requires approximately 14 to 21 days [6]. Escalating every seven days risks overshooting the IGF-1 target, which then requires dose reduction and restarts the steady-state clock.

Patients sometimes request faster escalation based on gym-culture advice or online forums. The correct response from a prescriber is to explain that faster dose increases create more instability, not faster results.

The HealthRX Sermorelin Escalation Decision Framework consolidates the escalation logic into three checkpoints:

1. Tolerance check (every 2 weeks): Any edema, arthralgia, or glucose elevation? If yes, hold. If no, proceed to the next 100-mcg step.
2. IGF-1 lab check (every 4 to 6 weeks): Is IGF-1 in the lower half of the reference range? If yes, escalate. At mid-range, hold. Above range, reduce by 100 mcg.
3. Clinical response check (every 8 weeks): Has the patient noticed improved sleep quality, recovery, or body composition? These subjective markers matter, but they never override the IGF-1 number.

Practical Injection Technique

Correct technique reduces both waste and discomfort.

Reconstitution and Storage

Sermorelin acetate is supplied as a lyophilized powder. Mix with bacteriostatic water (typically 2 to 5 mL per vial depending on concentration) per pharmacy instructions. Swirl gently. Do not shake. Once reconstituted, store at 2 to 8 degrees Celsius. Discard after 30 days. Do not freeze the reconstituted solution.

Injection Steps

1. Allow the vial to reach room temperature for 10 minutes before drawing.
2. Wipe the injection site with an alcohol swab and let it dry for 20 seconds.
3. Use a 29- or 31-gauge, 0.5-inch insulin syringe for abdominal or thigh injection.
4. Pinch a small fold of skin, insert at 45 to 90 degrees depending on body fat, and inject slowly.
5. Do not rub the site after injection; gentle pressure with a dry swab is sufficient.

Missing a single nightly dose has minimal clinical consequence given sermorelin's mechanism. Do not double the next dose. Resume the regular schedule the following night [7].

Side Effects and Dose-Adjustment Triggers

Sermorelin's side-effect profile is driven primarily by downstream IGF-1 and GH activity, not the peptide itself.

Common and Dose-Related

• Injection-site redness or itching: Typically resolves within 30 minutes. Persistent reactions may indicate preservative sensitivity; consult the compounding pharmacy about alternative formulations.
• Flushing: Most common at doses above 300 mcg. Usually transient (5 to 10 minutes post-injection). Rare above week 4 as tachyphylaxis develops.
• Headache: Often corresponds to rapid IGF-1 increase. Slow the titration schedule rather than reaching for analgesics nightly.
• Fluid retention: Reduce dose by 100 mcg and reassess in two weeks.

Less Common

• Somnolence: GH and IGF-1 do have sleep-modulatory effects. Most patients interpret this as improved sleep. When somnolence is excessive or extends into daytime hours, consider reducing the dose or shifting the injection 60 to 90 minutes earlier in the evening [8].
• Hyperglycemia: Elevated GH transiently antagonizes insulin. Patients with prediabetes or type 2 diabetes require more frequent glucose monitoring during titration. The American Diabetes Association 2024 Standards of Care note that GH excess is associated with insulin resistance; this pharmacological parallel is clinically relevant [9].

Contraindications That Override Titration

Stop sermorelin and do not re-escalate if:

• Active malignancy (any type) is diagnosed, because GH axis stimulation may promote tumor growth [10].
• Proliferative or pre-proliferative diabetic retinopathy develops.
• Intracranial hypertension is diagnosed.
• The patient becomes pregnant.

Sermorelin vs. Exogenous HGH: Why Titration Differs

Recombinant human growth hormone (rhGH) is dosed to replace GH directly, bypassing pituitary feedback. Sermorelin works upstream: it stimulates the pituitary to release GH in pulses, preserving the negative-feedback loop that prevents excess GH secretion. This physiologic preservation is the reason sermorelin's titration schedule can afford to be slower and more conservative. Overshoot is self-limiting to some degree because elevated IGF-1 feeds back to suppress further GH release from the pituitary. With rhGH, no such brake exists.

A 2004 head-to-head study comparing sermorelin with GH in adults with GH deficiency (N=30) found comparable IGF-1 normalization at 6 months, with sermorelin's group showing fewer episodes of IGF-1 above the upper reference limit (12% vs. 27% of measurements) [11]. That difference reflects the feedback brake.

Off-Label Adult Use: Regulatory Context

The FDA approved Geref (sermorelin acetate for injection) for pediatric GH deficiency in 1997. Serono voluntarily withdrew Geref from the US market in 2008 for commercial (not safety) reasons. Adult use today relies on compounded sermorelin acetate prepared by 503A or 503B outsourcing facilities. The FDA does not recognize sermorelin as a bulk drug substance currently eligible for 503A compounding, and its regulatory status has been actively debated since the FDA's 2023 proposed rule on peptides. Prescribers and patients should verify current compounding eligibility with a licensed pharmacy before initiating therapy [12].

Monitoring Beyond IGF-1

IGF-1 is necessary but not sufficient. A complete monitoring panel during sermorelin titration includes:

| Lab | Frequency | Rationale | |-----|-----------|-----------| | IGF-1 | Every 4 to 6 weeks during titration | Primary efficacy marker | | Fasting glucose | Every 4 to 6 weeks | GH-mediated insulin antagonism | | HbA1c | Every 3 months in patients with prediabetes/T2DM | Cumulative glucose exposure | | Lipid panel | Baseline and every 6 months | GH axis affects lipid metabolism | | Cortisol (morning) | Baseline | Rule out adrenal insufficiency before starting | | Thyroid panel (TSH, free T4) | Baseline | GH can unmask central hypothyroidism |

The Endocrine Society recommends that patients initiating GH axis therapies have thyroid function assessed at baseline, because GH administration can convert subclinical central hypothyroidism to overt hypothyroidism by increasing peripheral T4-to-T3 conversion [4]. The same consideration applies to GHRH analogues.

Special Populations: Dose Modification Principles

Patients Over 60

Age-related decline in somatotroph reserve means older adults produce less GH per unit of GHRH stimulus. The starting dose recommendation does not change, but the escalation ceiling should be lower: aim for IGF-1 in the lower-to-mid reference range for the 55 to 65 age bracket rather than the upper half. Many patients over 60 find that 200 to 300 mcg nightly is both sufficient and better tolerated.

Patients With Obesity (BMI >30)

Obesity blunts GH pulsatility and raises the IGF-1 clearance rate. Patients with a BMI above 30 may require a higher dose to reach the same IGF-1 target. Weight loss of 10% or more (whether from diet, exercise, or GLP-1 receptor agonist therapy) can significantly improve pituitary GH reserve, sometimes allowing dose reduction. Reassess IGF-1 after meaningful weight loss.

Patients on Glucocorticoids

Chronic glucocorticoid use suppresses GH secretion and IGF-1 production independently of sermorelin dose. These patients may appear non-responsive; the correct action is to optimize (or taper) glucocorticoid dosing with the managing physician before concluding that sermorelin has failed.